[go: up one dir, main page]

NO327988B1 - Galantaminsammensetning med kontrollert frigivelse - Google Patents

Galantaminsammensetning med kontrollert frigivelse Download PDF

Info

Publication number
NO327988B1
NO327988B1 NO20012857A NO20012857A NO327988B1 NO 327988 B1 NO327988 B1 NO 327988B1 NO 20012857 A NO20012857 A NO 20012857A NO 20012857 A NO20012857 A NO 20012857A NO 327988 B1 NO327988 B1 NO 327988B1
Authority
NO
Norway
Prior art keywords
galantamine
formulation according
water
coating
controlling membrane
Prior art date
Application number
NO20012857A
Other languages
English (en)
Norwegian (no)
Other versions
NO20012857D0 (no
NO20012857L (no
Inventor
Paul Marie Victor Gilis
Valentin Florent Victor De Conde
John Paul Mcgee
Marc Maurice Germain De Weer
Herman Johannes Catherina De Bruijn
Frederick Anne Rodolf Van Dycke
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO327988(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20012857D0 publication Critical patent/NO20012857D0/no
Publication of NO20012857L publication Critical patent/NO20012857L/no
Publication of NO327988B1 publication Critical patent/NO327988B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
NO20012857A 1998-12-24 2001-06-08 Galantaminsammensetning med kontrollert frigivelse NO327988B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98204447 1998-12-24
PCT/EP1999/010257 WO2000038686A1 (en) 1998-12-24 1999-12-20 Controlled release galantamine composition

Publications (3)

Publication Number Publication Date
NO20012857D0 NO20012857D0 (no) 2001-06-08
NO20012857L NO20012857L (no) 2001-06-08
NO327988B1 true NO327988B1 (no) 2009-11-02

Family

ID=8234559

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20012857A NO327988B1 (no) 1998-12-24 2001-06-08 Galantaminsammensetning med kontrollert frigivelse

Country Status (35)

Country Link
US (3) US7160559B1 (zh)
EP (1) EP1140105B1 (zh)
JP (1) JP2002533396A (zh)
KR (1) KR100437105B1 (zh)
CN (1) CN100370990C (zh)
AP (1) AP1414A (zh)
AR (2) AR022008A1 (zh)
AT (1) ATE252386T1 (zh)
AU (1) AU775914B2 (zh)
BG (1) BG65306B1 (zh)
BR (1) BR9916835A (zh)
CA (1) CA2358062C (zh)
CZ (1) CZ301658B6 (zh)
DE (1) DE69912311T2 (zh)
DK (1) DK1140105T3 (zh)
EA (1) EA004936B1 (zh)
EE (1) EE04996B1 (zh)
ES (1) ES2211215T3 (zh)
HR (1) HRP20010463B1 (zh)
HU (1) HUP0104778A3 (zh)
ID (1) ID29021A (zh)
IL (2) IL143899A0 (zh)
MY (1) MY122411A (zh)
NO (1) NO327988B1 (zh)
NZ (1) NZ511643A (zh)
OA (1) OA11740A (zh)
PL (1) PL349501A1 (zh)
PT (1) PT1140105E (zh)
SI (1) SI1140105T1 (zh)
SK (1) SK287676B6 (zh)
TR (1) TR200101822T2 (zh)
TW (1) TWI262079B (zh)
UA (1) UA79578C2 (zh)
WO (1) WO2000038686A1 (zh)
ZA (1) ZA200105132B (zh)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2351347A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EE04996B1 (et) * 1998-12-24 2008-04-15 Janssen Pharmaceutica N.V. Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
CA2310950C (en) * 2000-04-03 2005-11-08 Janssen Pharmaceutica N.V. An efficacious dosage regiment of galantamine that reduces side effects
CA2310926C (en) * 2000-04-03 2002-10-15 Janssen Pharmaceutica N.V. A use of galantamine for the treatment of neuropsychiatric behaviour associated with alzheimer's disease
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
AU2002340232A1 (en) * 2001-10-17 2003-04-28 Eisai Co., Ltd. Methods for treating substance abuse with cholinesterase inhibitors
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
DE10235556A1 (de) * 2002-08-03 2004-02-19 Hf Arzneimittelforschung Gmbh Medikament und Verfahren zur Verringerung des Alkohol- und/oder Tabakkonsums
ES2708551T3 (es) 2002-12-20 2019-04-10 Niconovum Ab Material particulado que contiene nicotina con una celulosa cristalina
ITMI20030827A1 (it) * 2003-04-18 2004-10-19 Unihart Corp Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
US7250258B2 (en) 2003-12-15 2007-07-31 Pgxhealth Llc CDK5 genetic markers associated with galantamine response
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
EP2340813A1 (en) * 2003-12-31 2011-07-06 Actavis Group PTC ehf. Solid dosage formulations of galantamine
EP1763337A2 (en) * 2003-12-31 2007-03-21 Actavis Group HF Immediate, controlled and sustained release formulations of galanthamine
GB0408308D0 (en) * 2004-04-14 2004-05-19 Vectura Ltd Pharmaceutical compositions
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
EP1830886B1 (en) * 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CA2604617C (en) * 2005-04-28 2014-06-17 Eisai R&D Management Co., Ltd. Composition containing anti-dementia drug
EP1933816A1 (en) * 2005-09-05 2008-06-25 Ranbaxy Laboratories, Ltd. Galantamine-containing controlled release oral dosage forms, processes for the preparation thereof and use for the manufacture of a medicament
US20070092568A1 (en) * 2005-10-10 2007-04-26 Gore Subhash P Galantamine compositions
JP5694645B2 (ja) 2006-03-16 2015-04-01 ニコノヴァム エービーＮｉｃｏｎｏｖｕｍ Ａｂ 改善された嗅ぎたばこ組成物
EP2010158B1 (en) * 2006-04-26 2016-02-17 Alphapharm Pty Ltd. Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
WO2008062426A2 (en) * 2006-08-02 2008-05-29 Emcure Pharmaceuticals Limited Formulation of benzazepine derivatives
WO2008048469A2 (en) * 2006-10-13 2008-04-24 Actavis Group Pct Hf Controlled-release coated dosage forms containing galantamine
DE102006056697A1 (de) * 2006-11-30 2008-06-05 Ratiopharm Gmbh Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung
AU2008213744B2 (en) * 2007-02-09 2013-12-05 Alphapharm Pty Ltd A dosage form containing two or more active pharmaceutical ingredients in different physical forms
KR100782310B1 (ko) 2007-03-22 2007-12-06 현대약품 주식회사 갈란타민 또는 이의 약학적으로 허용 가능한 염을 포함하는약학 조성물
US20090035370A1 (en) * 2007-08-02 2009-02-05 Drugtech Corporation Dosage form and method of use
WO2009024858A1 (en) * 2007-08-22 2009-02-26 Aurobindo Pharma Limited Controlled release dosage form of galantamine
WO2009043914A1 (en) * 2007-10-05 2009-04-09 Krka, D.D., Novo Mesto Multi particulate matrix system containing galantamine
EP2044933A1 (en) * 2007-10-05 2009-04-08 KRKA, D.D., Novo Mesto Multi particulate matrix system containing galantamine
CA2615137A1 (en) * 2007-12-17 2009-06-17 Pharmascience Inc. Single layered controlled release therapeutic system
ATE545410T1 (de) * 2008-05-09 2012-03-15 Ratiopharm Gmbh Galanthaminhaltiges arzneimittel mit kontrollierter freisetzung
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2503996A2 (en) 2009-11-26 2012-10-03 USV Limited Controlled release pharmaceutical compositions of galantamine
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
GR1007767B (el) 2011-07-26 2012-11-19 Φαρματεν Αβεε, Φαρμακευτικο σκευασμα παρατεταμενης αποδεσμευσης περιεχον γκαλανταμινη και μεθοδος για την παρασκευη αυτου
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
AU2013334874B2 (en) 2012-10-25 2018-04-05 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
CA2921308A1 (en) 2013-08-16 2015-02-19 Universiteit Maastricht Treatment of cognitive impairment with pde4 inhibitor
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US9849125B1 (en) 2015-11-03 2017-12-26 Banner Lifie Sciences LLC Anti-overingestion dosage forms
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
US20190240194A1 (en) 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
US20180333365A1 (en) * 2017-05-19 2018-11-22 Biscayne Neurotherapeutics, Inc. Modified release pharmaceutical compositions of huperzine and methods of using the same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
US20190247331A1 (en) 2018-02-15 2019-08-15 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213394B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Felelõsségû Társaság Composition and method for treating neurological disease
US10213393B1 (en) 2018-02-15 2019-02-26 Osmotica Kereskedelmi és Szolgáltató Korlátolt Feleõsségû Társaság Composition and method for treating neurological disease
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
JP7621940B2 (ja) 2018-11-19 2025-01-27 スパーナス ファーマシューティカルズ インコーポレイテッド 高用量の放出調節フペルジン製剤の使用
SG11202106117SA (en) 2018-12-10 2021-07-29 Massachusetts Gen Hospital Cromolyn esters and uses thereof
BG67408B1 (bg) 2019-04-12 2022-01-17 Софарма Ад Перорален лекарствен състав с растителен алкалоид, за лечение на зависимости
US12458622B2 (en) 2020-04-06 2025-11-04 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE450087B (sv) * 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
JP2755403B2 (ja) 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
CA1326632C (en) * 1988-10-26 1994-02-01 Bonnie Davis Long-active drug formulations comprising galanthamine for treatment of alzheimer's disease
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
DE4010079A1 (de) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) 1990-03-29 1996-05-21 Lts Lohmann Therapie-Systeme Gmbh + Co. Kg Pharmaceutic formulation for the treatment of alcoholism
AT397345B (de) 1990-04-04 1994-03-25 Chemiefaser Lenzing Ag Pharmazeutisches präparat mit verzögerter wirkstofffreisetzung auf basis von hemicellulosen
JP2542122B2 (ja) * 1990-04-18 1996-10-09 旭化成工業株式会社 球状核、球形顆粒およびその製造方法
US5336675A (en) 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
EP0515301A3 (en) * 1991-05-14 1993-06-16 Ernir Snorrason Improvements in benzodiazepine treatment by cholinesterterase inhibitors
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE4301782C1 (de) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE4301783C1 (de) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Galanthamin als wirksamem Bestandteil
DK0707475T3 (da) * 1993-06-14 1997-12-29 Janssen Pharmaceutica Nv Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
DE4319760A1 (de) * 1993-06-15 1994-12-22 Bayer Ag Ipsapiron Arzneimittelzubereitung
EP0711166A1 (en) * 1993-07-22 1996-05-15 Warner-Lambert Company Controlled release tacrine drug delivery systems and methods for preparing same
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
DE4342174C1 (de) * 1993-12-10 1995-05-11 Lohmann Therapie Syst Lts Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
GB9514821D0 (en) 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
JP3833314B2 (ja) * 1995-09-08 2006-10-11 武田薬品工業株式会社 発泡性組成物およびその製造方法
JP3693270B2 (ja) 1995-10-12 2005-09-07 旭化成ケミカルズ株式会社 フィルムコーティング顆粒およびその製造方法
SE9504537D0 (sv) * 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
JP3134187B2 (ja) * 1996-03-07 2001-02-13 武田薬品工業株式会社 放出制御組成物
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
NZ335813A (en) * 1996-11-19 2001-05-25 Procter & Gamble Blister card and compliance information package for complex oral dose regimen
JPH10231242A (ja) * 1997-02-20 1998-09-02 Taiyo Yakuhin Kogyo Kk 持続性ジクロフェナクナトリウム組成物
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
TW477702B (en) * 1997-10-23 2002-03-01 Dev Center Biotechnology Controlled release tacrine dosage form
AU1282099A (en) 1997-10-29 1999-05-17 Bonnie M. Davis Method for treatment of disorders of attention
CA2351347A1 (en) 1998-11-23 2000-06-02 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
EE04996B1 (et) * 1998-12-24 2008-04-15 Janssen Pharmaceutica N.V. Reguleeritud vabanemisega galantamiinipreparaat, meetod selle valmistamiseks, seda sisaldav doseerimisvorm ning farmatseutiline pakend
AUPP891299A0 (en) 1999-02-26 1999-03-25 Fujisawa Pharmaceutical Co., Ltd. New 6-membered cyclic compounds
US6273260B1 (en) * 2000-03-08 2001-08-14 Eli Lilly And Company Pharmaceutical packaging system

Also Published As

Publication number Publication date
CA2358062C (en) 2006-12-19
NO20012857D0 (no) 2001-06-08
US20060062856A1 (en) 2006-03-23
NZ511643A (en) 2003-07-25
DK1140105T3 (da) 2004-02-23
ATE252386T1 (de) 2003-11-15
KR20010075715A (ko) 2001-08-09
CN1331596A (zh) 2002-01-16
AR022008A1 (es) 2002-09-04
AR066313A2 (es) 2009-08-12
TWI262079B (en) 2006-09-21
US7160559B1 (en) 2007-01-09
ES2211215T3 (es) 2004-07-01
BG65306B1 (bg) 2008-01-31
SK8862001A3 (en) 2002-02-05
OA11740A (en) 2005-05-13
ID29021A (id) 2001-07-26
IL143899A0 (en) 2002-04-21
UA79578C2 (en) 2007-07-10
BG105564A (en) 2002-01-31
SI1140105T1 (en) 2004-04-30
HRP20010463B1 (hr) 2011-02-28
BR9916835A (pt) 2001-09-25
CZ20012182A3 (cs) 2002-01-16
TR200101822T2 (tr) 2001-11-21
EA200100713A1 (ru) 2001-12-24
MY122411A (en) 2006-04-29
EE04996B1 (et) 2008-04-15
HRP20010463A2 (en) 2002-08-31
IL143899A (en) 2006-04-10
CN100370990C (zh) 2008-02-27
HK1043062A1 (zh) 2002-09-06
HUP0104778A2 (hu) 2002-04-29
NO20012857L (no) 2001-06-08
CZ301658B6 (cs) 2010-05-19
AU775914B2 (en) 2004-08-19
US20060093671A1 (en) 2006-05-04
DE69912311T2 (de) 2004-07-29
EA004936B1 (ru) 2004-10-28
PT1140105E (pt) 2004-03-31
PL349501A1 (en) 2002-07-29
AU2100600A (en) 2000-07-31
WO2000038686A1 (en) 2000-07-06
KR100437105B1 (ko) 2004-06-23
HUP0104778A3 (en) 2004-05-28
SK287676B6 (sk) 2011-05-06
CA2358062A1 (en) 2000-07-06
DE69912311D1 (de) 2003-11-27
AP2001002219A0 (en) 2001-09-30
ZA200105132B (en) 2002-06-21
AP1414A (en) 2005-06-13
EP1140105B1 (en) 2003-10-22
EE200100319A (et) 2002-10-15
EP1140105A1 (en) 2001-10-10
JP2002533396A (ja) 2002-10-08

Similar Documents

Publication Publication Date Title
NO327988B1 (no) Galantaminsammensetning med kontrollert frigivelse
KR101489401B1 (ko) 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
KR101643219B1 (ko) 40-o-(2-히드록시)에틸-라파마이신을 포함하는 제약 조성물
US20180161280A1 (en) Pharmaceutical compositions comprising everolimus
US20080254131A1 (en) Controlled-release galantamine formulations
CA3107139C (en) Extended release compositions comprising trihexyphenidyl
US11911515B2 (en) Extended release compositions comprising pyridostigmine
MXPA01006529A (en) Controlled release galantamine composition
HK1043062B (zh) 控释加兰他敏组合物
HK1196567A (zh) 包含40-o-(2-羟基)乙基-雷帕霉素的药物组合物
HK1196567B (zh) 包含40-o-(2-羟基)乙基-雷帕霉素的药物组合物

Legal Events

Date Code Title Description
MK1K Patent expired